Am­gen wants in on obe­si­ty. But it's still work­ing on rare dis­ease, too

Am­gen tout­ed its rare dis­ease strat­e­gy on Thurs­day, high­light­ing the fi­nan­cial po­ten­tial of both cur­rent block­busters and oth­er drugs in its pipeline.

The spot­light on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.